Silodosin Provides Rapid, Effective Relief of Urinary Symptoms in Men With Benign Prostatic Hyperplasia: Presented at AUA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Silodosin Provides Rapid, Effective Relief of Urinary Symptoms in Men With Benign Prostatic Hyperplasia: Presented at AUA

By Bruce Sylvester

CHICAGO -- April 30, 2009 -- Silodosin produces fast and significant improvements in urinary symptoms associated with benign prostatic hyperplasia (BPH), according to an analysis of pooled data from 2 clinical trials presented here at the 2009 American Urological Association (AUA) Annual Meeting.

"In these phase 3 trials, silodosin provided rapid and effective relief of all irritative and obstructive symptoms," said presenter and lead investigator Leonard Marks, MD, University California Los Angeles School of Medicine, Los Angeles, California, on April 29.

The study was a post hoc analysis of pooled data from 2 identically designed, randomised, placebo-controlled, double-blind trials in which a total of 923 men, aged 50 years and older, with signs and symptoms of BPH were randomised to either silodosin 8 mg/day (n = 466) or a placebo (n = 457) for 12 weeks.

The men had a peak urine flow rate (Qmax) of between 4 and 15 mL/second, with a mean rate of 8.7 to 8.9, and an International Prostate Symptom Score (IPSS) >=13 (mean, 21.3).

For the post hoc analysis, the investigators assessed changes in IPSS subscales measuring irritative symptoms (frequency, urgency, and nocturia) and obstructive symptoms of BPH (incomplete emptying, intermittency, weak stream, and straining).

They reported that, from baseline, men treated with silodosin achieved statistically significant changes in all IPSS subscales, with the exception of nocturia.

Notably, the improvements in symptoms, except for nocturia, were rapidly and statistically significantly better for silodosin-treated patients than for placebo subjects, within 3 to 4 days of first treatment (P < .001). These significant differences lasted throughout 12 weeks of treatment. (P < .0001; P = .0037 for nocturia).

Funding for this study was provided by Watson Pharmaceuticals.

[Presentation title: Rapid Response of Irritative and Obstructive Urinary Symptoms of Benign Prostatic Hyperplasia to Treatment With Silodosin in 2 Randomized Studies. Abstract 1921]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities